CTLA4 and hepatocellular carcinoma: As shown in Figure 9G–J, the value of CTLA4− PD1−-IPS and CTLA4+ PD1+-IPS in the low risk group was higher than in the high risk group (p < 0.05), indicating that HCC patients in the low risk group showed significant therapeutic effects with anti-CTLA4 therapy and anti-PD1 therapy.